Medisch Spectrum Twente
Enschede, Overijssel, 7512 KZ, Netherlands
Location status: Recruiting
Location contact
Mattienne van der Kamp, MSc
CONTACT
Vera Hengeveld, MD
CONTACT
NCT Number: NCT06702735
Asthma is a common childhood disease that is characterized by chronic airway inflammation and episodic expiratory airflow obstruction. Asthma symptoms can impair participation in play and sports and have a negative impact on quality of life. It can be challenging for children to adequately feel and report their symptoms. Some children experience more symptoms than expected based on lung function during these symptoms, whereas others experience less symptoms than expected. This is also called 'symptom perception'.
A tool was developed to visualize symptoms, lung function and accessory symptom perception: The Rainbow tool. The aim of this study was to identify asthmatic children with a poor perception and investigate if their symptom perception could be improved by regular lung function measurements and personal feedback based on the Rainbow Tool.
Hypothesis: Measuring lung function en symptoms and provide personal feedback on perception based on the Rainbow tool has a positive effect on perception of asthma-related symptoms in asthmatic children.
Interested in participating?
Request Info7 year–15 year
All sexes
Interventional
Not applicable
Enschede, Overijssel, 7512 KZ, Netherlands
Location status: Recruiting
Mattienne van der Kamp, MSc
CONTACT
Vera Hengeveld, MD
CONTACT
Asthma is a common childhood disease that is characterized by chronic airway inflammation and episodic expiratory airflow obstruction. Asthma symptoms can impair participation in play and sports and have a negative impact on quality of life. It can be challenging for children to adequately feel and report their symptoms. Some children experience more symptoms than expected based on lung function during these symptoms, whereas others experience less symptoms than expected. This is also called 'symptom perception'.
A tool was developed to visualize symptoms, lung function and accessory symptom perception: The Rainbow tool. The Rainbow tool is a two-dimensional color-coded plot, visualizing the relationship between lung function, denoted as a percentage of personal best (FEV1) on the vertical axis, and VAS score on the horizontal axis. The FEV1 as a percentage of personal best on the vertical axis ranges from 30% to 100% since a maximal VAS score would be expected with a change in FEV1 to ≤ 30% of personal best. The horizontal axis ranges from 0 to 10, with 0 indicating no dyspnea and 10 maximal dyspnea. There are four color-coded zones: the green zone, yellow zone, orange zone, and red zone. The green zone indicates good alignment between symptoms and lung function, and thus a good symptom perception. It forms a diagonal band from the upper left (around 100% FEV1 and VAS score of 0) stretching to the lower right (around 30% FEV1 and VAS score of 10). The green zone is followed by the yellow, orange, and red zones on either side, indicating an increasing deviation in symptom perception from the ideal and respectively mild, moderate, and severe disconcordance between FEV1 and VAS score. The aim of this study was to identify asthmatic children with a poor perception and investigate if their symptom perception could be improved by regular lung function measurements and personal feedback based on the Rainbow Tool.
Hypothesis: Measuring lung function en symptoms and provide personal feedback on perception based on the Rainbow tool has a positive effect on perception of asthma-related symptoms in asthmatic children.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Selection phase:
Intervention phase:
Exclusion criteria
The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
Feedback sessions with health care professional based on the Rainbow tool.
Time frame: Two week run-in versus last week of intervention
The difference in the average perception score (0-100) during the two-week run-in and last week of the intervention between the intervention group (with feedback) and the control group
Time frame: Measured per week during the study period, which is 8 weeks
Difference between average perception score of intervention group (with feedback) and intervention (without feedback) group per week
Time frame: Measured per week during the study period, which is 8 weeks
Perception scores (0-100) and average perception score per week. Including over- or underperception
Time frame: Measured per week during the study period, which is 8 weeks
Number of perception scores in green/yellow/red zone (absolute and relative) per week
Time frame: Measured per week during the study period, which is 8 weeks
Type of additional symptom when measurement (lung function + VAS) is performed: no additional symptoms, cough, wheezing, chest pain, feeling dizzy, nasal symptoms
Time frame: Per study phase, 2 weeks for selection phase, 3 weeks for intervention phase and 3 weeks for follow-up phase
Number of patients that drop-out during or after selection phase and reasons for drop-out
Time frame: After the intervention phase, that takes 3 weeks
User experience based on semi-structured interview and user experience + technology acceptance questionnaire after the intervention phase
Contact information is provided by the study sponsor or research team.
Mattienne van der Kamp, MSc, PhD
CONTACT
Vera Hengeveld, MD
CONTACT
Medisch Spectrum Twente
Other
The Rainbow Study - a Randomized Controlled Trial to Evaluate the Effect of Personalized Feedback on Symptom Perception in Asthmatic Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07232550
Asthma, Asthma in Children
Warsaw, Poland
View Trial DetailsNCT06201494
Asthma, Asthma in Children
Prague, Czechia
View Trial DetailsNCT05004714
Asthma in Children, Implementation
District Heights, Maryland, United States
View Trial DetailsNCT06159127
Asthma, Asthma in Children
Cincinnati, Ohio, United States
View Trial Details